zalunfiban
Phase 3Small molecule
zalunfiban is one of 2 small molecule programs targeting ST-elevation Myocardial Infarction (STEMI). It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in ST-Elevation Myocardial Infarction (STEMI)
#DrugCompanyPhaseTrials
1Jardiance
Boehringer IngelheimPhase 2
zalunfiban
CCeleCor Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for zalunfiban. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCeleCor Therapeutics